535 A phase I/II study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors

• Israel Lowy,
• Roman Groisberg,
• Nehal Lakhani,
• Melissa Mathias,
• Siyu Li,
• Melissa Johnson,
• Frank Seebach,
• Matthew Fury,
• Hyunsil Han,
• Kerry Casey,
• Dimitris Skokos

Affiliations

Israel Lowy

8Regeneron, Tarrytown, NY, USA

Roman Groisberg

Aff1 0000 0001 2291 4776grid.240145.6Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Unit 455, Division of Cancer MedicineThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd. 77030 Houston TX USA

Nehal Lakhani

4START Midwest, Grand Rapids, MI, USA

Melissa Mathias

20 Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA

Siyu Li

21 Regeneron Pharmaceuticals, Inc, Basking Ridge, New Jersey, USA

Melissa Johnson

3Sarah Cannon Research Institute, Nashville, TN, USA

Frank Seebach

9Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA

Matthew Fury

9Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA

Hyunsil Han

4Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Kerry Casey

4Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Dimitris Skokos

4Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA